Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Increases By 136.0%

Aadi Bioscience, Inc. (NASDAQ:AADI) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 31st total of 232,000 shares. Based on an average daily volume of 322,600 shares, the short-interest ratio is currently 1.7 days. Approximately 2.7% of the company’s stock are short sold.

Hedge Funds Weigh In On Aadi Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Peapod Lane Capital LLC bought a new stake in Aadi Bioscience during the 4th quarter worth approximately $1,397,000. XTX Topco Ltd acquired a new stake in shares of Aadi Bioscience during the third quarter worth $32,000. BML Capital Management LLC bought a new stake in Aadi Bioscience in the 3rd quarter valued at $4,120,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Aadi Bioscience in the 2nd quarter worth $37,000. 52.08% of the stock is owned by institutional investors.

Aadi Bioscience Price Performance

Shares of NASDAQ:AADI opened at $2.89 on Thursday. The stock has a market capitalization of $71.24 million, a price-to-earnings ratio of -1.27 and a beta of 0.65. Aadi Bioscience has a fifty-two week low of $1.21 and a fifty-two week high of $3.81. The business’s fifty day moving average price is $2.81 and its two-hundred day moving average price is $2.16.

Aadi Bioscience (NASDAQ:AADI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) earnings per share for the quarter, meeting the consensus estimate of ($0.46). The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same period in the prior year, the business posted ($0.60) earnings per share. Research analysts expect that Aadi Bioscience will post -2.04 EPS for the current fiscal year.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.